Alterations of immune reactivity by haloperidol and delta-9-tetrahydrocannabinol.
Studies were performed to determine whether delta 9-tetrahydrocannabinol (THC) or haloperidol suppress or ablate humoral or cellular immune responses against sheep erythrocytes. Both agents produced dose-dependent reductions in hemolytic plaque-forming cell (PFC) numbers at the time or peak reactivity (Day 4) in vehicle-treated, control mice. However, both delta 9-THC and haloperidol only delayed the time of peak PFC formation by 24-48 hours. These changes in kinetics of humoral immune responsiveness took place at doses of delta 9-THC and haloperidol that produced signs of gross behavioral toxicity. Neither Delta-9-THC, cannabinol (CBN) or cannabidiol (CBD) had an effect on the titer of serum hemagglutinating antibody measured seven days after immunization. Further, haloperidol did not alter the delayed-type hypersensitivity response to dinitroflorobenzene (DNFB).
D000818:Animals; D000917:Antibody Formation / Q000187:drug effects; D001522:Behavior, Animal / Q000187:drug effects; D013759:Dronabinol / Q000494:pharmacology*; D006220:Haloperidol / Q000494:pharmacology*; D006386:Hemagglutination Tests; D006462:Hemolytic Plaque Technique; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007109:Immunity / Q000187:drug effects*; D007111:Immunity, Cellular / Q000187:drug effects; D008297:Male; D051379:Mice
D013759:Dronabinol; D006220:Haloperidol